TY - JOUR
T1 - MR1-independent activation of human mucosal-associated invariant T cells by mycobacteria
AU - Suliman, Sara
AU - Murphy, Melissa
AU - Musvosvi, Munyaradzi
AU - Gela, Anele
AU - Meermeier, Erin W.
AU - Geldenhuys, Hennie
AU - Hopley, Christiaan
AU - Toefy, Asma
AU - Bilek, Nicole
AU - Veldsman, Ashley
AU - Hanekom, Willem A.
AU - Johnson, John L.
AU - Boom, W. Henry
AU - Obermoser, Gerlinde
AU - Huang, Huang
AU - Hatherill, Mark
AU - Lewinsohn, David M.
AU - Nemes, Elisa
AU - Scriba, Thomas J.
N1 - Funding Information:
This work was supported by the European Commission–funded TBVAC2020 Consortium (H2020-PHC-643381) and the Bill and Melinda Gates Foundation (OPP1066265). The bacille Calmette–Guérin revaccination trial was supported by the
Funding Information:
Tuberculosis Research Unit at Case Western Reserve University, established with funds from the National Institutes of Allergy and Infectious Diseases/ National Institutes of Health/Department of Health and Human Services (N01-AI95383 and HHSN266200700022C/NO1-AI-70022) and National Institutes of Health Grant R01-AI087915. S.S. was supported by the Carnegie Corporation and a South Africa National Research Foundation Innovation Fellowship. E.N. is an International Society for Advancement of Cytometry Marylou Ingram Scholar.
Publisher Copyright:
©. 2019 The Authors.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Tuberculosis (TB) is the leading cause of mortality from a single infectious agent, Mycobacterium tuberculosis. Relevant immune targets of the partially efficacious TB vaccine bacille Calmette-Guérin (BCG) remain poorly defined. Mucosal-associated invariant T (MAIT) cells are MHC-related protein 1 (MR1)-restricted T cells, which are reactive against M. tuberculosis, and underexplored as potential TB vaccine targets. We sought to determine whether BCG vaccination activated mycobacteria-specific MAIT cell responses in humans. We analyzed whole blood samples from M. tuberculosis-infected South African adults who were revaccinated with BCG after a six-month course of isoniazid preventative therapy. In vitro BCG stimulation potently induced IFN-g expression by phenotypic (CD8+CD26+CD161+) MAIT cells, which constituted the majority (75%) of BCG-reactive IFN-g- producing CD8+ T cells. BCG revaccination transiently expanded peripheral blood frequencies of BCG-reactive IFN-g+ MAIT cells, which returned to baseline frequencies a year following vaccination. In another cohort of healthy adults who received BCG at birth, 53% of mycobacteria-reactive-activated CD8 T cells expressed CDR3a TCRs, previously reported as MAIT TCRs, expressing the canonical TRAV1-2-TRAJ33 MAIT TCRa rearrangement. CD26 and CD161 coexpression correlated with TRAV1-2+CD161+ phenotype more accurately in CD8+ than CD42CD82 MAIT cells. Interestingly, BCG-induced IFN-g expression by MAIT cells in vitro was mediated by the innate cytokines IL-12 and IL-18 more than MR1-induced TCR signaling, suggesting TCR-independent activation. Collectively, the data suggest that activation of blood MAIT cells by innate inflammatory cytokines is a major mechanism of responsiveness to vaccination with whole cell vaccines against TB or in vitro stimulation with mycobacteria.
AB - Tuberculosis (TB) is the leading cause of mortality from a single infectious agent, Mycobacterium tuberculosis. Relevant immune targets of the partially efficacious TB vaccine bacille Calmette-Guérin (BCG) remain poorly defined. Mucosal-associated invariant T (MAIT) cells are MHC-related protein 1 (MR1)-restricted T cells, which are reactive against M. tuberculosis, and underexplored as potential TB vaccine targets. We sought to determine whether BCG vaccination activated mycobacteria-specific MAIT cell responses in humans. We analyzed whole blood samples from M. tuberculosis-infected South African adults who were revaccinated with BCG after a six-month course of isoniazid preventative therapy. In vitro BCG stimulation potently induced IFN-g expression by phenotypic (CD8+CD26+CD161+) MAIT cells, which constituted the majority (75%) of BCG-reactive IFN-g- producing CD8+ T cells. BCG revaccination transiently expanded peripheral blood frequencies of BCG-reactive IFN-g+ MAIT cells, which returned to baseline frequencies a year following vaccination. In another cohort of healthy adults who received BCG at birth, 53% of mycobacteria-reactive-activated CD8 T cells expressed CDR3a TCRs, previously reported as MAIT TCRs, expressing the canonical TRAV1-2-TRAJ33 MAIT TCRa rearrangement. CD26 and CD161 coexpression correlated with TRAV1-2+CD161+ phenotype more accurately in CD8+ than CD42CD82 MAIT cells. Interestingly, BCG-induced IFN-g expression by MAIT cells in vitro was mediated by the innate cytokines IL-12 and IL-18 more than MR1-induced TCR signaling, suggesting TCR-independent activation. Collectively, the data suggest that activation of blood MAIT cells by innate inflammatory cytokines is a major mechanism of responsiveness to vaccination with whole cell vaccines against TB or in vitro stimulation with mycobacteria.
UR - http://www.scopus.com/inward/record.url?scp=85075227618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075227618&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1900674
DO - 10.4049/jimmunol.1900674
M3 - Article
C2 - 31611259
AN - SCOPUS:85075227618
SN - 0022-1767
VL - 203
SP - 2917
EP - 2927
JO - Journal of Immunology
JF - Journal of Immunology
IS - 11
ER -